Stock & Company Details
Erasca Inc $ERAS
Price:
N/A
N/A
350M
$5.4B
52 Week High:
N/A
10 Day Average Volume:
N/A
-16.57
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
ERAS technical indicators
Latest Erasca Inc (ERAS) indicator readings as of 2026-10-09.
ERAS's 14-day RSI is 55.6, in neutral territory. At $16.03 it is trading 12.4% above its 200-day moving average of $14.26, and below its 50-day average of $16.55. Price sits near the upper Bollinger Band ($13.52 to $16.29). ADX reads 16.4, indicating a range-bound market rather than a trend.
Overview
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Finance Bot
Ask your questions
Start by typing a question below.
